Skip to main
BCPC
BCPC logo

Balchem (BCPC) Stock Forecast & Price Target

Balchem (BCPC) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Balchem Corp reported $255.5 million in top-line revenue for 2Q25, exceeding estimates and reflecting a 1% year-over-year increase, alongside a sequential rise from the previous quarter. The company's price-to-earnings (P/E) multiple increased slightly from 38.8x to 39.6x, indicating positive investor sentiment and contributing to an elevated market perception. Additionally, expectations for improving gross and net margins, alongside the potential for the company to achieve a debt-free status and engage in accretive M&A activities, bolster the overall optimistic outlook on Balchem's financial health.

Bears say

Balchem Corp faces several risks that contribute to a negative outlook, including slower-than-anticipated growth in its core businesses and ongoing inflationary pressures that could impact profitability. The company's reliance on successful product launches in the nutrition sector is jeopardized by a potential inability to introduce new offerings, further complicating revenue generation. Additionally, challenges stemming from the approval process of a drug candidate by its partner, Curemark, along with potential disruptions to operations in Europe due to regional conflicts, could hinder business performance and investor sentiment.

Balchem (BCPC) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Balchem (BCPC) Forecast

Analysts have given Balchem (BCPC) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Balchem (BCPC) has a Strong Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $189, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $189, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Balchem (BCPC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.